hotspot
An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.
The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.
advertisement
“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Can we make enough H5N1 bird flu vaccine if there's a pandemic?
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
